Eyenovia's Presentation at AAO 2024 Expo
Eyenovia, Inc. (NASDAQ: EYEN), a pioneering company in ophthalmic technology, is making waves in the medical community with its presentation at the prestigious AAO 2024 Expo. This significant event is set to take place from October 19 to 21 in Chicago, where experts from around the globe gather to share insights and advancements in the field of ophthalmology.
Exciting Study Results Revealed
The focal point of Eyenovia's presentation will be the groundbreaking results from their Phase 3 study, designated CPN-302. This study centers around clobetasol propionate suspension 0.05% (APP13007), which has recently garnered approval from the U.S. Food and Drug Administration. This approval is a landmark achievement, as it serves as a treatment strategy for managing inflammation and alleviating pain following ocular surgeries.
Launch and Commercial Availability
Eyenovia is enthusiastic about the recent U.S. launch of clobetasol, which commenced on September 26, 2024. The company recognizes the urgency of addressing post-surgical challenges and believes this product will significantly enhance patient care. Michael Rowe, the Chief Executive Officer of Eyenovia, expressed his excitement regarding the study's outcomes, indicating that these findings marked a new chapter in ophthalmic treatment.
Rapid Results and Enhanced Safety Profile
According to Mr. Rowe, the Phase 3 study not only demonstrated swift relief from inflammation and pain—within just four days post-surgery—but also highlighted rapid improvements in visual acuity. These promising results are further bolstered by a safety profile that is deemed desirable, ensuring that healthcare professionals can recommend clobetasol with confidence.
Presentation Highlights
Details of the presentation include:
- Title: Clobetasol Propionate Ophthalmic Suspension 0.05% (APP 13007) for the Treatment of Postsurgical Inflammation and Pain (Study CPN-302)
- Presenter: Dr. Jeffrey H Levenson from Levenson Eye Associates
- Date/Time: Available on-demand throughout the AAO Expo
About Eyenovia, Inc.
Eyenovia is committed to innovation in the ophthalmic domain, focusing on developing an advanced pipeline of products through its unique Optejet platform. The company continues to work on commercializing Mydcombi for pupil dilation, alongside further developing clobetasol for post-surgical treatment. Future endeavors also include the late-stage development of solutions for pediatric progressive myopia, along with exploring licensing opportunities for additional uses.
Contact Information
For those interested in learning more about Eyenovia or their presented products, the company can be contacted directly:
- Eyenovia Contact:
Andy Jones, Chief Financial Officer
Email: ajones@eyenovia.com - Eyenovia Investor Contact:
Eric Ribner, LifeSci Advisors, LLC
Email: eric@lifesciadvisors.com
Phone: (646) 751-4363 - Eyenovia Media Contact:
Norbert Lowe, Vice President, Commercial Operations
Email: nlowe@eyenovia.com
Frequently Asked Questions
What was the main focus of Eyenovia's presentation at AAO Expo?
The primary focus was on the results of the Phase 3 study of clobetasol propionate suspension 0.05%, highlighting its effectiveness for post-surgical inflammation and pain relief.
When was clobetasol launched?
Clobetasol was launched on September 26, 2024, marking a significant milestone for Eyenovia in terms of product availability.
Who presented the study at the expo?
The study was presented by Dr. Jeffrey H Levenson from Levenson Eye Associates.
How quickly can clobetasol relieve symptoms after surgery?
Patients can expect significant relief from inflammation and pain as soon as four days after surgery when using clobetasol.
What is Eyenovia's vision for their products in the market?
Eyenovia aims to position clobetasol as the preferred choice for post-operative care due to its effectiveness and safety profile.
